Mark Slee

7.9k total citations
41 papers, 518 citations indexed

About

Mark Slee is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Neurology. According to data from OpenAlex, Mark Slee has authored 41 papers receiving a total of 518 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pathology and Forensic Medicine, 10 papers in Molecular Biology and 9 papers in Neurology. Recurrent topics in Mark Slee's work include Multiple Sclerosis Research Studies (14 papers), Acute Lymphoblastic Leukemia research (6 papers) and Peripheral Neuropathies and Disorders (5 papers). Mark Slee is often cited by papers focused on Multiple Sclerosis Research Studies (14 papers), Acute Lymphoblastic Leukemia research (6 papers) and Peripheral Neuropathies and Disorders (5 papers). Mark Slee collaborates with scholars based in Australia, Canada and Italy. Mark Slee's co-authors include Michael Donaghy, Helmut Butzkueven, Michael Barnett, Jeannette Lechner‐Scott, Steve Vucic, Tim Spelman, Małgorzata Krupa, Stephen Bacchi, Dominic Thyagarajan and Eugenio Pucci and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Neurology.

In The Last Decade

Mark Slee

39 papers receiving 507 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Slee Australia 12 257 214 111 91 82 41 518
M. Cossburn United Kingdom 10 495 1.9× 241 1.1× 120 1.1× 75 0.8× 42 0.5× 17 687
M. S. Freedman Canada 9 411 1.6× 177 0.8× 108 1.0× 88 1.0× 21 0.3× 16 536
Sibyl Wray United States 14 442 1.7× 175 0.8× 157 1.4× 59 0.6× 29 0.4× 58 628
Jeffrey Palmer United States 10 303 1.2× 105 0.5× 132 1.2× 78 0.9× 16 0.2× 28 499
Franz Felix Konen Germany 13 340 1.3× 181 0.8× 78 0.7× 82 0.9× 16 0.2× 42 509
Elisabetta Verdun di Cantogno United States 11 380 1.5× 139 0.6× 93 0.8× 36 0.4× 18 0.2× 23 437
Alexandra Degenhardt United Kingdom 9 655 2.5× 243 1.1× 137 1.2× 98 1.1× 25 0.3× 10 769
Csilla Rózsa Hungary 16 217 0.8× 219 1.0× 37 0.3× 97 1.1× 51 0.6× 32 535
D Malapert France 9 149 0.6× 294 1.4× 56 0.5× 53 0.6× 131 1.6× 14 531
Sten Öhman Sweden 10 411 1.6× 270 1.3× 87 0.8× 102 1.1× 33 0.4× 16 652

Countries citing papers authored by Mark Slee

Since Specialization
Citations

This map shows the geographic impact of Mark Slee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Slee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Slee more than expected).

Fields of papers citing papers by Mark Slee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Slee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Slee. The network helps show where Mark Slee may publish in the future.

Co-authorship network of co-authors of Mark Slee

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Slee. A scholar is included among the top collaborators of Mark Slee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Slee. Mark Slee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sanfilippo, Paul G., Chao Zhu, Olga Skibina, et al.. (2025). Menopause Impact on Multiple Sclerosis Disability Progression. JAMA Neurology. 82(12). 1219–1219.
2.
Butzkueven, Helmut, Tomáš Kalinčík, Francesco Patti, et al.. (2024). Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies. Therapeutic Advances in Neurological Disorders. 17. 4223502419–4223502419. 2 indexed citations
3.
Bacchi, Stephen, et al.. (2024). Glucocorticoid‐induced adrenal suppression: physiological basis and strategies for glucocorticoid weaning. The Medical Journal of Australia. 220(10). 539–539. 1 indexed citations
4.
Stretton, Brandon, Aashray Gupta, Annabel Sorby‐Adams, et al.. (2024). Prognostic significance of paramagnetic rim lesions in multiple sclerosis: A systematic review. Journal of Clinical Neuroscience. 129. 110810–110810. 3 indexed citations
5.
Xavier, Alexandre, Jim Stankovich, Vicki E. Maltby, et al.. (2023). Parity is associated with long-term differences in DNA methylation at genes related to neural plasticity in multiple sclerosis. Clinical Epigenetics. 15(1). 20–20. 6 indexed citations
6.
Stringer, Brett W., Vanessa M. Conn, Youichirou Ootsuka, et al.. (2023). Functional Characterisation of the Circular RNA, circHTT(2-6), in Huntington’s Disease. Cells. 12(9). 1337–1337. 3 indexed citations
7.
Xavier, Alexandre, Vicki E. Maltby, Ewoud Ewing, et al.. (2023). DNA Methylation Signatures of Multiple Sclerosis Occur Independently of Known Genetic Risk and Are Primarily Attributed to B Cells and Monocytes. International Journal of Molecular Sciences. 24(16). 12576–12576. 7 indexed citations
8.
Maltby, Vicki E., Alexandre Xavier, Ewoud Ewing, et al.. (2023). Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis. Neurology. 101(7). e679–e689. 11 indexed citations
9.
10.
Slee, Mark, et al.. (2023). Defining progression independent of relapse activity (PIRA) in adult patients with relapsing multiple sclerosis: A systematic review✰. Multiple Sclerosis and Related Disorders. 78. 104899–104899. 26 indexed citations
11.
Kovoor, Joshua G., et al.. (2023). Incidence and Characteristics of Melanoma in Multiple Sclerosis Patients Treated With Fingolimod: A Systematic Review. Current Dermatology Reports. 12(4). 300–313. 1 indexed citations
12.
Ward, Michael, Mark Slee, Ty Stanford, et al.. (2021). Utilisation of disease modifying treatment and diversity of treatment pathways in relapsing remitting multiple sclerosis. Multiple Sclerosis and Related Disorders. 57. 103412–103412. 2 indexed citations
13.
Worley, Paul, Michael Lowe, Sarah Strasser, et al.. (2019). The Northern Territory Medical Program – growing our own in the NT. Rural and Remote Health. 19(2). 4671–4671. 6 indexed citations
14.
Kalinčík, Tomáš, Nathaniel Lizak, Vilija Jokubaitis, et al.. (2016). Australian cladribine experience. Multiple Sclerosis Journal. 22. 289–290.
15.
Kister, Ilya, Tim Spelman, Raed Alroughani, et al.. (2016). Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. Journal of Neurology Neurosurgery & Psychiatry. 87(10). 1133–1137. 64 indexed citations
16.
Slee, Mark, et al.. (2016). CSF hypotension: A review of its manifestations, investigation and management. Journal of Clinical Neuroscience. 34. 39–43. 31 indexed citations
17.
Jokubaitis, Vilija, Tim Spelman, Jeannette Lechner‐Scott, et al.. (2013). The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform. PLoS ONE. 8(3). e59694–e59694. 40 indexed citations
18.
Slee, Mark, et al.. (2013). Muscle-specific kinase antibody positive myaesthenia gravis and multiple sclerosis co-presentation: A case report and literature review. Journal of Neuroimmunology. 264(1-2). 130–133. 7 indexed citations
19.
Krupa, Małgorzata, et al.. (2009). Clinical, electrophysiological and genetic features of a large Australian family with paramyotonia congenita. The Medical Journal of Australia. 190(8). 456–456. 4 indexed citations
20.
Slee, Mark, et al.. (2005). Speech‐activated myoclonus: An uncommon form of action myoclonus. Movement Disorders. 20(9). 1120–1126. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Cossburn Breakdown of academic impact, for papers by M. S. Freedman Breakdown of academic impact, for papers by Sibyl Wray Breakdown of academic impact, for papers by Jeffrey Palmer Breakdown of academic impact, for papers by Franz Felix Konen Breakdown of academic impact, for papers by Elisabetta Verdun di Cantogno Breakdown of academic impact, for papers by Alexandra Degenhardt Breakdown of academic impact, for papers by Csilla Rózsa Breakdown of academic impact, for papers by D Malapert Breakdown of academic impact, for papers by Sten Öhman
Rankless by CCL
2026